NCT00516438View on ClinicalTrials.gov

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

November 30, 2009

Conditions
Malignant Solid Tumors
Interventions
DRUG

KU-0059436 (AZD2281)(PARP inhibitor)

oral

DRUG

Topotecan

intravenous infusion

Trial Locations (3)

Unknown

Research Site, Glasgow

Research Site, Leicester

Research Site, Manchester

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
collaborator

KuDOS Pharmaceuticals Limited

INDUSTRY

lead

AstraZeneca

INDUSTRY